INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses

por Sulzmaier, Florian J, Kern, Nadja, Ahn, Sae Jeong, Polovina, Anya, Ho, Jason, Hussain, Abrahim, Cyprus, Garrett, Macedo, Chelsie, Pandit, Rajay, Crago, William, Rowell, Emily, Timmer, John C, Eckelman, Brendan P
Publicado 2023

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

por Subbiah, Vivek, Chawla, Sant P., Conley, Anthony P., Wilky, Breelyn A., Tolcher, Anthony, Lakhani, Nehal J., Berz, David, Andrianov, Vasily, Crago, William, Holcomb, Monica, Hussain, Abrahim, Veldstra, Carson, Kalabus, James, O’Neill, Brianne, Senne, Lane, Rowell, Emily, Heidt, Analeah B., Willis, Katelyn M., Eckelman, Brendan P.
Publicado 2023